Insider Selling: Zeltiq Aesthetics Director Unloads 29,157 Shares of Stock (ZLTQ)
Zeltiq Aesthetics (NASDAQ:ZLTQ) Director Jean George unloaded 29,157 shares of the stock in a transaction dated Thursday, July 31st. The shares were sold at an average price of $20.09, for a total transaction of $585,764.13. The sale was disclosed in a document filed with the SEC, which is available at this link.
A number of research firms have recently commented on ZLTQ. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday. Separately, analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Zeltiq Aesthetics presently has an average rating of “Buy” and an average target price of $24.26.
Zeltiq Aesthetics (NASDAQ:ZLTQ) traded down 5.15% on Thursday, hitting $20.24. The stock had a trading volume of 1,857,808 shares. Zeltiq Aesthetics has a 52 week low of $6.67 and a 52 week high of $24.79. The stock’s 50-day moving average is $15.94 and its 200-day moving average is $17.84. The company’s market cap is $757.8 million.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. The company’s quarterly revenue was up 79.1% on a year-over-year basis. Analysts expect that Zeltiq Aesthetics will post $-0.39 EPS for the current fiscal year.
Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.